As the synergy between HDAC inhibitors and venetoclax (BCL2 inhibitor) was shown for patients with advanced-stage cutaneous T-cell lymphoma and glioblastoma [58,59], we researched this phenomenon in leukemia and NB sells. Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.